The global end stage renal disease drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). End stage kidney disease, also known as the late-stage renal disease, refers to a medical condition when chronic kidney disease reaches an advanced or its last stage. In this disease, the kidneys fail to work, as they otherwise function in order to meet the body's needs. The market growth for their drugs is majorly attributed to the growing number of patients suffering from kidney failure, all over the globe. Factors that increase the risk of end stage renal disease include smoking, hypertension, diabetes, and the geriatric population. In fact, the most common factor includes diabetes, whereas hypertension (high blood pressure) is considered to be the second most frequent cause of this disease. 

According to the National Kidney Foundation (NKD), approximately 10% of the global population suffers from chronic kidney diseases and millions die each year. As per the same source, the geriatric population suffers the condition most in emerging economies such as China and India. The number of patients continues to increase at a rate of 5-7% per year. Chronic kidney disease is estimated to be more common in women than men (15% vs 12%). Adding to this, the constantly growing number of patients suffering from hypertension and diabetes are also likely to fuel the end stage renal disease drugs market growth. As per the World Health Organization (WHO), in 2019, around 1.13 billion people globally had hypertension. Adding to this, from 2014-2016, hypertension and diabetes were responsible for nearly 75% of the global kidney failure cases. 

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Type

o By Application

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape:  Pfizer Inc., Novartis International AG, and Eli Lilly and Co., among others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global End Stage Renal Disease Drugs Market Report by Segment

By Type 

• Calcium Succinate

• Mk-3866

• Sanguinate

• Pacritinib

• Others

By Application

• Hospitals

• Clinics

• Research Institutes

Global End Stage Renal Disease Drugs Market Report by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa